Modified Dextrans - Fina Biosolutions

Expert Purveyor of High Quality Modified Dextrans

Power Your Specific Application with Our Reliable Dextran Polymers

Product Listing

For larger quantities, further pricing information and inquiries for custom products, please email sales@finabio.com.


Amino Dextrans



Antibody Dextran Conjugates



Monofunctionalized Dextrans



Fluorescent Dextrans



Amino-Ficoll Modified Dextrans



Streptavidin Dextran



High Ratio Maleimide Dextrans



Fluorescent Streptavidin Dextrans

Fina Biosolutions offers a unique portfolio of functionalized dextrans. We have worked with FinaBio for the last ten years. They have impressed us with the very high quality and reproducibility of their products. FinaBio provides outstanding technical support, prompt shipping and excellent communication. Their extensive product line is of great value when we undertake custom projects as well as opening up new applications areas.

- R & D Director

Life Sciences Company

We have been using your dextran products for the last decade. FinaBio’s attention to quality control means that we can count on the consistency and reproducibility of your reagents for our experiments.

- Laura Taylor, Ph.D. Senior Research Scientist

NYU School of Medicine

FinaBio’s ready-to-conjugate CRM-maleimide is extremely convenient to use. We have used it to create more than forty different conjugates for a conjugate vaccine project and couldn’t be happier with the results.

- Craig McElroy, PhD.

College of Pharmacy, OSU

We began working with Fina Biosolutions since learning of their efforts to make CRM₁₉₇ more affordable. FinaBio’s pricing allowed us to switch from using KLH to their EcoCRM^® (CRM₁₉₇) as the carrier protein for our substance use disorder vaccines. EcoCRM^® has performed very well in our preclinical studies and we are preparing for our phase 1 clinical trial. In addition to providing an excellent product, FinaBio has been responsive to our needs, providing support & expertise at every stage of the journey in developing our conjugate vaccine.

- Dr. Marco Pravetoni

University of Washington, Seattle